Blackstone Life Sciences to Provide J&J $750 Million for OLN324 Development
Funds managed by Blackstone Life Sciences will provide Johnson & Johnson with $750 million to support Phase 3 clinical development of OLN324, an investigational therapy for serious retinal vascular diseases.
Blackstone announced today that funds managed by Blackstone Life Sciences (“Blackstone”) will provide $750 million in development funding to Johnson & Johnson to support the Phase 3 clinical development of OLN324, an investigational therapy for serious retinal vascular diseases. Specifically, Black…